# A Clinical Trial to Evaluate the Safety and Immunogenicity of CH505M5 N197D mRNA-gp160 Followed by CH505 TF mRNA-gp160 in Adults in Overall Good Health Without HIV

> **NCT06557785** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 53 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **BIOLOGICAL:** CH505M5 N197D mRNA-gp160
- **BIOLOGICAL:** CH505 TF mRNA-gp160

## Key facts

- **NCT ID:** NCT06557785
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-11-25
- **Primary completion:** 2027-03-09
- **Final completion:** 2027-03-09
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2026-01-14

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06557785

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06557785, "A Clinical Trial to Evaluate the Safety and Immunogenicity of CH505M5 N197D mRNA-gp160 Followed by CH505 TF mRNA-gp160 in Adults in Overall Good Health Without HIV". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06557785. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*